Innoviva, Inc. (INVA)
- Previous Close
14.99 - Open
15.01 - Bid 15.09 x 400
- Ask 15.16 x 400
- Day's Range
15.01 - 15.14 - 52 Week Range
11.37 - 16.86 - Volume
23,522 - Avg. Volume
706,679 - Market Cap (intraday)
956.629M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
6.88 - EPS (TTM)
2.20 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 8, 2015
- 1y Target Est
15.00
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
www.inva.comRecent News: INVA
Performance Overview: INVA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INVA
Valuation Measures
Market Cap
947.78M
Enterprise Value
1.20B
Trailing P/E
6.81
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.19
Price/Book (mrq)
1.40
Enterprise Value/Revenue
3.88
Enterprise Value/EBITDA
5.12
Financial Highlights
Profitability and Income Statement
Profit Margin
57.89%
Return on Assets (ttm)
7.12%
Return on Equity (ttm)
28.97%
Revenue (ttm)
310.46M
Net Income Avi to Common (ttm)
179.72M
Diluted EPS (ttm)
2.20
Balance Sheet and Cash Flow
Total Cash (mrq)
193.51M
Total Debt/Equity (mrq)
66.53%
Levered Free Cash Flow (ttm)
120.6M
Research Analysis: INVA
Company Insights: INVA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: INVA
INVA: Raising target price to $16.00
INNOVIVA INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetINVA: What does Argus have to say about INVA?
INNOVIVA INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetINVA: Lowering target price to $15.00
INNOVIVA INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetINVA: What does Argus have to say about INVA?
INNOVIVA INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target